Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study

Abstract

297), text (3634), references (29) + 1 supplementary material Ratio (HR)=2•77 (95% CI 2•07-3•71) and (HR=3•83 (2•29-6•42)), respectively. On adjusted multivariable analysis, exposure to DAA was associated with a decrease in all cause-mortality (HR=0•48 (95% CI 0•33-0•70)) and HCC (HR=0•66 (0•46-0•93)), and was no longer associated with decompensated cirrhosis (HR=1•14 (0•57-2•27)). InterpretationDAA treatment is associated with a reduced risk of mortality and HCC and should be considered in all patients with chronic HCV infection.

Real‐world impact following initiation of interferon‐free hepatitis C regimens on liver‐related outcomes and all‐cause mortality among patients with compensated cirrhosis

“…In a large study of a cirrhotic HCV‐infected cohort by Backus et al, DAA treatment and consequent SVR was strongly associated with a reduced rate of mortality (reported adjusted HR of 0.26 for SVR compared with non‐SVR), as well as a significant reduction in HCC. In the French ANRS CO22 Hepather study, treatment with DAAs of the subpopulation with cirrhosis was also associated with a decrease in all‐cause mortality and HCC (adjusted HRs of 0.45 and 0.65, respectively, for treated compared with untreated patients) . The reductions in mortality associated with DAA treatment are comparable between the three distinct populations, which is reassuring.…”

Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases–Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection

“…Eradicating hepatitis C infection results in numerous health benefits, including reduced rates of all‐cause mortality, cirrhosis, hepatic decompensation, and HCC . Successful treatment also confers improvement in extrahepatic manifestations of HCV disease, including cryoglobulinemic vasculitis and HCV‐related non‐Hodgkin lymphoma and other lymphoproliferative disorders, as well as improved productivity and quality of life .…”

Direct‐acting antivirals and the risk of hepatocellular carcinoma: The end of a polemic?

“…By using weighting methodologies (IPTW, Cox models) given the heterogeneities of treated and untreated patients at least in countries where treatment prioritization was implemented, we established in the ANRS/AFEF Hepather cohort C0‐22 first a decreased risk of de novo HCC and second a significant decrease in global, hepatic and extra‐hepatic mortality in the former as compared to the latter results which are clearly reassuring: they underline the need of weighting methodologies to avoid misinterpretations.…”